Eliciting B cell immunity against infectious diseases using nanovaccines

Area of Science:

• Immunology
• Nanotechnology
• Infectious Diseases

Background:

• Emerging infectious diseases, including COVID-19, pose significant global health and economic threats.
• Effective vaccines are lacking for many critical infectious diseases such as HIV, malaria, and influenza.
• Developing new vaccines is hindered by a limited understanding of immune protection correlates.

Purpose of the Study:

• To provide a perspective on global trends in emerging nanoscale vaccines for infectious diseases.
• To describe the biological, experimental, and logistical challenges in nanovaccine development.
• To explore how immunoengineering can overcome these challenges.

Main Methods:

• Review of current global trends in nanovaccine technology for infectious diseases.
• Analysis of biological, experimental, and logistical hurdles in nanovaccine development.
• Discussion of immunoengineering strategies to address these challenges.

Main Results:

• Nanovaccines demonstrate potential for improved antigen presentation and sustained immune responses compared to conventional vaccines.
• Nanovaccines offer enhanced access to lymph nodes, crucial for effective immunization.
• Immunoengineering presents viable solutions for overcoming development obstacles.

Conclusions:

• Nanoscale vaccines represent a sophisticated technology to induce robust immune responses against challenging pathogens.
• Addressing biological, experimental, and logistical issues through immunoengineering is key to advancing nanovaccine development.
• Nanovaccines hold significant promise for combating current and future infectious disease threats.